TGFB1 and pulmonary fibrosis: Results demonstrated that LMWF treatment in bleomycin-induced pulmonary fibrosis mice decreased TGF-β, TNF-α, and IL-6 expression in lung tissue, mirroring the effects of nintedanib in reducing inflammatory cytokine accumulation.